- Home
- MEIP vs LFWD Comparison
MEIP vs LFWD Comparison
Compare MEIP & LFWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- LFWD
- Stock Information
- Founded
- MEIP 2000
- LFWD 2001
- Country
- MEIP United States
- LFWD Israel
- Employees
- MEIP N/A
- LFWD N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- LFWD
- Sector
- MEIP Health Care
- LFWD
- Exchange
- MEIP Nasdaq
- LFWD NYSE
- Market Cap
- MEIP 13.3M
- LFWD 15.8M
- IPO Year
- MEIP 2003
- LFWD 2014
- Fundamental
- Price
- MEIP $2.18
- LFWD $1.21
- Analyst Decision
- MEIP Hold
- LFWD Strong Buy
- Analyst Count
- MEIP 1
- LFWD 3
- Target Price
- MEIP N/A
- LFWD $9.00
- AVG Volume (30 Days)
- MEIP 6.4K
- LFWD 152.9K
- Earning Date
- MEIP 05-13-2025
- LFWD 05-15-2025
- Dividend Yield
- MEIP N/A
- LFWD N/A
- EPS Growth
- MEIP N/A
- LFWD N/A
- EPS
- MEIP N/A
- LFWD N/A
- Revenue
- MEIP N/A
- LFWD $25,414,000.00
- Revenue This Year
- MEIP N/A
- LFWD $12.04
- Revenue Next Year
- MEIP N/A
- LFWD $40.58
- P/E Ratio
- MEIP N/A
- LFWD N/A
- Revenue Growth
- MEIP 33.76
- LFWD 41.92
- 52 Week Low
- MEIP $1.46
- LFWD $1.18
- 52 Week High
- MEIP $4.10
- LFWD $4.77
- Technical
- Relative Strength Index (RSI)
- MEIP 53.30
- LFWD 39.21
- Support Level
- MEIP $2.05
- LFWD $1.21
- Resistance Level
- MEIP $2.25
- LFWD $1.27
- Average True Range (ATR)
- MEIP 0.11
- LFWD 0.06
- MACD
- MEIP 0.00
- LFWD 0.00
- Stochastic Oscillator
- MEIP 69.91
- LFWD 21.43
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.